|Bid||4.8900 x 200|
|Ask||4.9400 x 200|
|Day's Range||4.8401 - 4.9400|
|52 Week Range||0.0400 - 30.4100|
|PE Ratio (TTM)||-0.43|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
ST. PAUL, Minn., June 26, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company will join the Russell Microcap® Index effective after the U.S. market opens today. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "EnteroMedics is very pleased to be added to such a widely referenced index," said Dan Gladney, EnteroMedics President, Chief Executive Officer and Chairman of the Board.
ST. PAUL, Minn., June 21, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Scott Shikora, M.D, F.A.C.S., F.A.S.M.B.S., the Company's Consulting Medical Director, Professor of Surgery at Harvard Medical School and Director of the Center for Metabolic and Bariatric Surgery at Brigham and Women's Hospital in Boston, will present information about the Company's vBloc® Neurometabolic Therapy as part of a presentation on neuromodulation for the treatment of obesity. The presentation will take place at the upcoming XIX International Congress of Surgery for Obesity and Metabolic Diseases, June 28-July 1, Playa del Carmen, Mexico.
Q4 2016 EnteroMedics Inc Earnings Call